检查点抑制剂增加非感染性葡萄膜炎与重症肌无力风险
本研究基于大型商业与Medicare Advantage医保数据库开展回顾性队列研究,比较使用检查点抑制剂(CPI)与接受非检查点抑制剂(N-CPI)化疗的患者。多因素分析显示,CPI暴露者发生非感染性葡萄膜炎的风险比N-CPI组高(HR=2.09;95%CI 1.36-3.22,p=0.001),发生重症肌无力(MG)的风险也更高(HR=2.60;95%CI 1.34-5.07,p=0.005)。
要点
- CPI暴露者非感染性葡萄膜炎风险显著高于N-CPI化疗者(HR=2.09,p=0.001)。
- CPI暴露者重症肌无力风险也显著升高(HR=2.60,p=0.005)。
- 该研究提示使用CPI的患者需警惕上述免疫相关不良事件。
核心结论
- 与N-CPI化疗相比,CPI暴露与非感染性葡萄膜炎和重症肌无力风险升高相关。
研究设计与样本
- 回顾性队列研究,使用大型商业和Medicare Advantage医保索赔数据库。
- 暴露组为启动CPI(伊匹木单抗、帕博利珠单抗、纳武利尤单抗、阿替利珠单抗、阿维鲁单抗、西米普利单抗、度伐利尤单抗)的患者,对照组为接受N-CPI化疗的患者。
- 按人口学特征和索引年份以1:10匹配,采用多因素Cox比例风险回归模型分析。
主要发现
- 葡萄膜炎分析中,CPI组26例(0.3%)发生非感染性葡萄膜炎,N-CPI组123例(0.2%)。
- 多因素分析显示CPI组葡萄膜炎风险显著高于N-CPI组(HR=2.09;95%CI 1.36-3.22,p=0.001)。
- MG分析中,CPI组11例(0.1%)发生MG,N-CPI组36例(0.04%)。
- 多因素分析显示CPI组MG风险显著高于N-CPI组(HR=2.60;95%CI 1.34-5.07,p=0.005)。
关键数值与推荐
- 葡萄膜炎风险比较:HR=2.09(95%CI 1.36-3.22,p=0.001),CPI组 vs N-CPI组。
- MG风险比较:HR=2.60(95%CI 1.34-5.07,p=0.005),CPI组 vs N-CPI组。
临床怎么用
- 使用CPI的患者应警惕非感染性葡萄膜炎和重症肌无力的发生,出现相关症状时及时进行眼科和神经科评估。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
AIM: To determine if checkpoint inhibitors (CPIs) confer an increased risk of non-infectious uveitis or myasthenia gravis (MG) compared to patients on non-checkpoint inhibitor (N-CPI) chemotherapy. METHODS: A retrospective cohort study was performed comparing patients in a large commercial and Medicare advantage database exposed to CPI compared to N-CPI. All patients who initiated a CPI (ipilimumab, pembrolizumab, nivolumab, atezolizumab, avelumab, cemiplimab and durvalumab) were eligible. Date of earliest CPI in the exposure group and N-CPI chemotherapy in the comparator group was considered the index date. Exclusion occurred in both cohorts for any history of uveitis or MG diagnosis and having <1 year in the insurance plan prior to the index date, and <6 months in plan following the index date. Every exposed patient was matched up to 1:10 based on demographics and index year to patients on N-CPI chemotherapy. Multivariate Cox proportional hazards regression modelling was performed. RESULTS: For evaluation of incidence of non-infectious uveitis, 26 (0.3%) of 8678 patients on CPI and 123 (0.2%) of 76 153 N-CPI comparators were found to have non-infectious uveitis. After multivariate analysis, CPIs showed an increased hazard for uveitis compared to N-CPI (HR=2.09; 95% CI 1.36 to 3.22, p=0.001). For the MG analysis, 11 (0.1%) of 9210 patients developed MG in the CPI group and 36 (0.04%) of 80 620 comparators. The CPI cohort had a higher hazard of developing MG (HR=2.60; 95% CI 1.34 to 5.07, p=0.005) compared to controls in multivariate analysis. CONCLUSIONS: Exposure to CPI confers a higher risk for non-infectious uveitis and MG compared to N-CPI chemotherapy.
引用
- Xia T, Brucker AJ, McGeehan B, et al. Risk of non-infectious uveitis or myasthenia gravis in patients on checkpoint inhibitors in a large healthcare claims database. Br J Ophthalmol. 2020. PMID: 33087313. doi:10.1136/bjophthalmol-2020-317060
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。